FindTrial
Sign In

Understanding how anti-VEGF injection causes changes in eye and its visual outcomes in patients with neovascular age related macular degeneration

Effect of Anti-VEGF on evolution of Subretinal Hyperreflective Material(SHRM) and its correlation with visual function in Neovascular Age Related Macular Degeneration(AMD) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093841
Enrollment
33
Registered
2025-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H353- Degeneration of macula and posterior pole

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Sankara eye hospital, Bangalore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with neovascular age related macular degeneration. Underwent 3 loading doses of intravitreal anti-VEGF therapy. Clear media. Willing to comply with scheduled followup imaging and visual function testing. Consent to participate in the study.

Exclusion criteria

Exclusion criteria: Concurrent retinal pathologies like diabetic or hypertensive retinopathy or retinal vein occlusion History of uveitis or ocular inflammation. Previous vitreoretinal surgery in the study eye. Poor OCT image quality (less than 40 percentage) Other causes of CNV like myopia and angioid streaks. Subretinal hyperreflective hemorrhage more than 50 percentage of the lesion on OCT imaging.

Design outcomes

Primary

MeasureTime frame
To determine whether the qualitative pattern of SHRM change (e.g., complete resolution, partial regression, or transformation into fibrosis) over a 3-month period correlates with the degree of visual function improvement in patients undergoing anti-VEGF therapy for neovascular AMD. Timepoint: assessed at 4weeks and 8 weeks followup of last injection—

Secondary

MeasureTime frame
Predictive value of early SHRM change in forecasting 3-month visual outcome Timepoint: assessed at 4weeks & 8 weeks followup of last injection;Incidence of morphological transformation of SHRM to fibrosis. Timepoint: assessed at 4weeks & 8 weeks followup of last injection—

Countries

India

Contacts

Public ContactDr Brij Shah

Sankara Eye Hospital, Bangalore

drragraj@gmail.com90369 52706

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026